We selected two models to test the efficacy of the anti-IL-17A antibody treatment on BC-associated bone and lung metastasis: 1) the SKG mice challenged with 4 T1 tumors and 2) the PyV MT mice induced with CII. Here, IL17A is linked to breast cancer.